Peppermint Oil

Summary

Peppermint Oil (CHEMBL2108758) is a phase-3 clinical-stage unknown; indicated across 2 conditions including interstitial cystitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108758
Name	Peppermint Oil
Type	Unknown
Max phase	3

Also known as: Apercap, BT MINT 995888, Colomint, FEMA NO. 2848, Mentha x piperita oil, Mintec, Obbekjaers, Peppermint oil, Peppermint volatile oil, PEPPERMINT OIL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
interstitial cystitis	1	MONDO:0018301	EFO:0008507

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
Not specified	11
PHASE1	3
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02588248	PHASE3	TERMINATED	L-Menthol Injection as a Novel Technique During Colonoscopy
NCT04845217	PHASE1/PHASE2	RECRUITING	Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome
NCT05282706	PHASE1	ENROLLING_BY_INVITATION	Use of Aromatherapy in Conjunction With Physical/Occupational Therapy in an Acute Care Setting
NCT03295747	PHASE1	COMPLETED	Peppermint Oil Pharmacokinetics/Dynamics and Novel Biological Signatures in Children With Functional Abdominal Pain
NCT04497870	PHASE1	WITHDRAWN	Peppermint Oil Pharmacokinetics/Dynamics
NCT05613153	Not specified	ENROLLING_BY_INVITATION	Peppermint Oil as a Treatment for Children With Bladder and Bowel Dysfunction
NCT07318779	Not specified	NOT_YET_RECRUITING	Effect of Cardamom and Peppermint Oils on Chemotherapy-Related Nausea-Vomiting and Food Intake
NCT07326163	Not specified	ENROLLING_BY_INVITATION	The Effect of Peppermint Oil Aromatherapy on Pain, Functional Capacity and Cost in Fibromyalgia Patients
NCT02802241	Not specified	COMPLETED	Effects of Open-label vs Double-blind Treatment in IBS
NCT03286764	Not specified	COMPLETED	Use of Peppermint Oil During Screening Colonoscopy to Improve Visibility
NCT03370328	Not specified	COMPLETED	Reducing Up-set Stomach and Vomiting After Surgery Using Essential Oils
NCT03577496	Not specified	COMPLETED	Does Aromatherapy Decrease Postoperative Nausea and Vomiting?
NCT04659278	Not specified	WITHDRAWN	Endourage Complete Spectrum Oral Mucosal Drops (OMD) in Adults Desiring a Reduction in Ethanol Use
NCT05561543	Not specified	COMPLETED	Effects of Peppermint Oil in Mild-moderate Hypertension.
NCT05677698	Not specified	COMPLETED	Menoupausal Symptoms and Aromatherapy
NCT06914921	Not specified	COMPLETED	Enteric-Coated Peppermint Oil Versus Standard Antispasmodic in SLC6A4 (5-HTTLPR) Carriers With Irritable Bowel Syndrome.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).